Theravance Biopharma, Inc. Forecasted to Post FY2017 Earnings of ($4.95) Per Share (TBPH)
Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at Leerink Swann lifted their FY2017 EPS estimates for Theravance Biopharma in a note issued to investors on Wednesday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings per share of ($4.95) for the year, up from their previous forecast of ($5.10). Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2017 earnings at ($1.16) EPS, FY2018 earnings at ($4.75) EPS, FY2019 earnings at ($4.52) EPS, FY2020 earnings at ($3.78) EPS and FY2021 earnings at ($1.76) EPS.
TBPH has been the subject of several other reports. Evercore ISI assumed coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They set an “outperform” rating and a $45.00 target price for the company. BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. Finally, ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.86.
Theravance Biopharma (NASDAQ:TBPH) opened at $28.77 on Friday. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44. The company has a current ratio of 6.74, a quick ratio of 6.53 and a debt-to-equity ratio of 0.93.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after purchasing an additional 126,393 shares during the period. Vanguard Group Inc. grew its position in Theravance Biopharma by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock worth $127,379,000 after purchasing an additional 116,981 shares during the period. State Street Corp grew its position in Theravance Biopharma by 2.2% in the 2nd quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock worth $35,443,000 after purchasing an additional 19,428 shares during the period. Northern Trust Corp grew its position in Theravance Biopharma by 6.1% in the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock worth $21,117,000 after purchasing an additional 30,611 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Theravance Biopharma by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock valued at $12,160,000 after acquiring an additional 18,177 shares during the period. 84.54% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Frank Pasqualone bought 4,000 shares of the business’s stock in a transaction on Monday, August 21st. The stock was acquired at an average price of $26.34 per share, with a total value of $105,360.00. Following the transaction, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the sale, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.